Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
326.3 DKK | +1.65% | +1.30% | +10.47% |
04-08 | Denmark's Demant Finalizes Capital Reduction | MT |
04-04 | Competition Regulator Clears Cochlear’s Acquisition of Oticon Medical’s Cochlear Implant Business | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The company is in debt and has limited leeway for investment
- The company benefits from high valuations in earnings multiples.
- With an enterprise value anticipated at 3.59 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.47% | 10.01B | B- | ||
-12.39% | 21.33B | B | ||
-5.39% | 16.56B | A | ||
+5.90% | 13.49B | B | ||
-13.54% | 2.16B | - | ||
+6.74% | 1.83B | B+ | ||
+39.88% | 1.71B | D- | ||
+11.86% | 583M | - | ||
-.--% | 423M | - | - | |
+30.53% | 150M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DEMANT Stock
- Ratings Demant A/S